{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=LUCENTIS+%28Ranibizumab+Injection%29&page=3",
    "query": {
      "intervention": "LUCENTIS (Ranibizumab Injection)",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 206,
    "total_pages": 21,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=LUCENTIS+%28Ranibizumab+Injection%29&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=LUCENTIS+%28Ranibizumab+Injection%29&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-08T06:20:33.950Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00470977",
      "title": "Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Coats' Disease",
        "Idiopathic Retinal Telangiectasia",
        "Retinal Angiomatous Proliferation",
        "Polypoidal Choroidal Vasculopathy",
        "Pseudoxanthoma Elasticum",
        "Pathological Myopia",
        "Multi-focal Choroiditis",
        "Rubeosis Iridis",
        "Von Hippel Lindau Disease",
        "BEST VITELLIFORM MACULAR DYSTROPHY, MULTIFOCAL (Disorder)"
      ],
      "interventions": [
        {
          "name": "ranibizumab injection (0.5 mg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Manhattan Eye, Ear & Throat Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2007-05",
      "completion_date": "2010-12",
      "has_results": false,
      "last_update_posted_date": "2012-10-25",
      "last_synced_at": "2026-10-08T06:20:33.950Z",
      "location_count": 2,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00470977"
    },
    {
      "nct_id": "NCT02222207",
      "title": "Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Regorafenib, ophthalmic oily suspension (BAY73-4506)",
          "type": "DRUG"
        },
        {
          "name": "Sham IVT",
          "type": "PROCEDURE"
        },
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2014-10",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2016-09-08",
      "last_synced_at": "2026-10-08T06:20:33.950Z",
      "location_count": 37,
      "location_summary": "Tucson, Arizona • Arcadia, California • Beverly Hills, California + 34 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02222207"
    },
    {
      "nct_id": "NCT00390208",
      "title": "Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Age Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "ranibizumab, dexamethasone and verteporfin",
          "type": "DRUG"
        },
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bay Area Retina Associates",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2006-08",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2010-05-27",
      "last_synced_at": "2026-10-08T06:20:33.950Z",
      "location_count": 4,
      "location_summary": "Castro Valley, California • Walnut Creek, California • Riverdale, Georgia + 1 more",
      "locations": [
        {
          "city": "Castro Valley",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Riverdale",
          "state": "Georgia"
        },
        {
          "city": "Toledo",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00390208"
    },
    {
      "nct_id": "NCT01495208",
      "title": "Open Label to Study to Evaluate Effect of Alfilbercept on Patients With (FVPED) Fibrovascular Pigment Epithelial Detachment",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Fibrovascular Pigment Epithelial Detachment"
      ],
      "interventions": [
        {
          "name": "Aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vitreous -Retina- Macula Consultants of New York",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2011-12",
      "completion_date": "2012-10",
      "has_results": false,
      "last_update_posted_date": "2018-07-16",
      "last_synced_at": "2026-10-08T06:20:33.950Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01495208"
    },
    {
      "nct_id": "NCT00931489",
      "title": "Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Age Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "ranibizumab (Lucentis(R))",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lawrence S. Morse, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 131,
      "start_date": "2009-08",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-10-08T06:20:33.950Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00931489"
    },
    {
      "nct_id": "NCT00403039",
      "title": "Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Retinal Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "Ranibizumab (Lucentis )",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vitreous -Retina- Macula Consultants of New York",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 41,
      "start_date": "2006-11",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2016-01-01",
      "last_synced_at": "2026-10-08T06:20:33.950Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00403039"
    },
    {
      "nct_id": "NCT00454389",
      "title": "A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Epi-Rad90™ Ophthalmic System",
          "type": "DEVICE"
        },
        {
          "name": "ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "NeoVista",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 494,
      "start_date": "2007-04",
      "completion_date": "2012-08",
      "has_results": false,
      "last_update_posted_date": "2011-07-27",
      "last_synced_at": "2026-10-08T06:20:33.950Z",
      "location_count": 23,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 18 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00454389"
    },
    {
      "nct_id": "NCT00680225",
      "title": "Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Choroidal Melanoma"
      ],
      "interventions": [
        {
          "name": "Ranibizumab injection and TTT - ICG based",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New England Retina Associates",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 10,
      "start_date": "2007-09",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2017-04-12",
      "last_synced_at": "2026-10-08T06:20:33.950Z",
      "location_count": 1,
      "location_summary": "Hamden, Connecticut",
      "locations": [
        {
          "city": "Hamden",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00680225"
    },
    {
      "nct_id": "NCT00831350",
      "title": "Posterior Vitreous Detachment (PVD) Assessment During Dual Retinal Vein Occlusion (RVO) Lucentis Evaluations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Retinal Vein Occlusion",
        "Posterior Vitreous Detachment"
      ],
      "interventions": [
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Barnes Retina Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2009-04",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2017-10-30",
      "last_synced_at": "2026-10-08T06:20:33.950Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00831350"
    },
    {
      "nct_id": "NCT01926977",
      "title": "Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neovascular Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Ranibizumab 0.5mg",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept 2.0mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arshad Khanani",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2013-09",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2016-03-03",
      "last_synced_at": "2026-10-08T06:20:33.950Z",
      "location_count": 1,
      "location_summary": "Reno, Nevada",
      "locations": [
        {
          "city": "Reno",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01926977"
    }
  ]
}